


FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SF0941K1 US		SERIAL NO.: 09/980,545	
INFORMATION DISCLOSURE STATEMENT FOR PATENT (Use several sheets if necessary)				APPLICANT: Fridman et al.			
				FILING DATE: November 15, 2001		GROUP:	
U.S. PATENT DOCUMENTS							
EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
XZ	AA	WO 97/04097	02/1997	PCT	C12N	15/12	X
	AB	WO 99/14240	03/1999	PCT	C07K	1/705	X
	AC	DE 298 20 466 U1	04/1999	GERMANY	C07K	14/79	X
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
XZ	AC	Tartour et al., 1998, <i>Proceedings of the American Association for Cancer Research</i> 39:3 Abstract No. 4447 p. 653					
	AD	Wakasugi et al., 1998, <i>Proceeding of the American Association for Cancer Research</i> 39:3 Abstract No. 37 p. 6					
	AE	Laan et al., 1999, <i>The Journal of Immunology</i> 162:2347-52					
	AF	Antonyamy et al., 1999, <i>The Journal of Immunology</i> 162:577-84					
	AG	Fossiez et al., 1998, <i>Immunol</i> 16:541-551					
	AH	Pages et al., 1999, <i>Immunology Letters</i> 68:135-139					
	AI	Tartour et al., 1999, <i>J. Cancer Research</i> 59:3698-3704					
	AJ	Spriggs, 1997, <i>Journal of Clinical Immunology</i> 17(5) 366-369					
	AK	Yao et al., 1995, <i>The Journal of Immunology</i> 155:5483-5486					
EXAMINER				DATE CONSIDERED			
				3/29/06			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Express Mail Label: EV532027670US

PTO/SB/08a (08-03)  
Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

**Complete if Known**

Application Number	09/980,545
Filing Date	03/27/2000
First Named Inventor	FRIDMAN, Herve W.
Art Unit	1646
Examiner Name	Xiaozhen Xie
Attorney Docket Number	SF0941K1 US

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
X2	AA	WO 97/04097	02/06/1997	PCT		
↓	AB	WO 99/14240	03/25/1999	PCT		
↓	AC	DE 298 20 466 U1	05/20/1999	GERMANY		

Examiner Signature		Date Considered	3/29/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label: EV532027670US


PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/980,545		
		Filing Date	03/27/2000		
		First Named Inventor	FRIDMAN, Herve W.		
		Art Unit	1646		
		Examiner Name	Xiaozhen Xie		
Sheet	2	of	5	Attorney Docket Number	SF0941K1 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
XZ	AD	International Search Report for PCT/US 00/08081 - 6 Pages	
	AE	Tartour et al., IL17, a T cell derived cytokine which promotes the in vivo growth of cervical tumors in nude mice, 6001 Chemical Abstracts 39, No. 4447, p. 693, XP -002129053 (March 1998)	
	AF	Wakasugi et al., Tumorigenicity of cancer cells transfected with IL-17 gene in vivo, 6001 Chemical Abstracts 39, No. 37, p 6, XP-002129054 (March 1998)	
	AG	Tartour, et al., Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of Human Cervical Tumors in Nude Mice, Cancer Research, Vol. 59:3698-3704 (August 1999)	
	AH	Benchetrit et al., Interleukin-17 inhibits tumor cell growth by means of a T-Cell dependent Mechanism, Blood, Vol. 99:6, 2114-2121 (March 2002)	
	AI	Pages et al, Control of tumor development by intratumoral cytokines, Immunology Letters, Vol. 68:135-139 (May 1999)	
	AJ	Fossiez et al., Interleukin-17, Intern. Rev. Immunol. 16:541-551 (May 1998)	
	AK	Laan et al., Neutrophil Recruitment by Human IL-17 Via C-X-C Chemokine Release in the Airways, Journal of Immunology 162: 2347-2352 (February 1999)	
	AL	Antonyssamy et al., Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the functional Differentiation of Dendritic Cell Progenitors, Journal of Immunology 162:577-584 (January 1999)	
	AM	Spriggs, Interleukin-17 and Its Receptor, Journal of Clinical Immunology Vol. 17:5, 366-369 (September 1997)	

Examiner Signature		Date Considered	3/29/06
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:


PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	09/980,545
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Filing Date	11/15/2001
		First Named Inventor	FRIDMAN, Herve W.
		Art Unit	1646
		Examiner Name	Xiaozhen Xie
		Attorney Docket Number	SF0941K1 US
Sheet	3	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
X2	AN	Yao, et al., Human IL-17: A Novel Cytokine Derived from T Cells, Journal of Immunology 155:5483-5486 (December 1995)	
	AO	Schiffman et al., The Epidemiology of Cervical Carcinogenesis, Cancer 76:1888-1901 (1995)	
	AP	Eustace et al., Interleukin-6(IL-6) Functions as an Autocrine Growth Factor in Cervical Carcinomas in Vitro, Gynecol. Oncol. 50:15-19 (1993)	
	AQ	Woodworth et al, Comparative Lymphokine Secretion by Cultured Normal Human Cervical Keratinocytes, Papillomavirus-Immortalized, and Carcinoma Cell Lines, Am. J. Pathol. 142:1544-1555 (May 1993)	
	AR	Singh et al., Expression of Interleukin 8 Correlates with the Metastatic Potential of Human Melanoma Cells in Nude Mice, Cancer Research 54:3242-3247 (June 1994)	
	AS	Attur et al, Interleukin-17 Up-Regulation of Nitric Oxide Production In Human Osteoarthritis Cartilage, Arthritis & Rheumatism 40:1050-1053 (June 1997)	
	AT	Iglesias et al., Interleukin-6 and Interleukin-6 Soluble Receptor Regulate Proliferation of Normal, Human Papillomavirus-Immortalized, and Carcinoma-Derived Cervical Cells in Vitro, Am. J. Pathol 146:944-952 (1995)	
	AU	Fridman et al., Cytokines and Cell Regulation, Molec. Aspects Med. 18:1-90 (1997)	
✓	AV	Vink et al., Mouse Plasmacytoma Growth In Vivo: Enhancement by Interleukin 6 (IL-6) and Inhibition by Antibodies Directed against IL-6 or Its Receptor, J. Exp. Med. 172:997-1000 (1990)	

Examiner Signature		Date Considered	3/29/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	09/980545
		Filing Date	03/27/2000
		First Named Inventor	FRIDMAN, Herve W.
		Art Unit	1646
		Examiner Name	Xiaozhen Xie
		Attorney Docket Number	SF0941K1 US
Sheet	4	of	5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
XZ	AW	Durandy et al., Role of IL-6 in Promoting Growth of Human EBV-Induced B-Cell Tumors in Severe Combined Immunodeficient Mice, J. Immunol. 152:5361-5367 (1994)	
	AX	Bataille et al., Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma, Blood 86:685-691 (July 1995)	
	AY	Schadendorf et al., IL-8 Produced by Human Malignant Melanoma Cells in Vitro Is an Essential Autocrine Growth Factor, J. Immunol. 151:2667-2675 (September 1993)	
	AZ	Rouvier et al., CTLA-8, Cloned from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene, J. Immunol. 150: 5445-5456 (1993)	
	BA	Fossiez et al., T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hematopoietic Cytokines J. Exp. Med 183:2593-2603 (June 1996)	
	BB	Mittrucker et al., CD2-mediated Autocrine Growth of Herpes Virus Saimiri-transformed Human T Lymphocytes, J. Exp. Med 176:909-913 (September 1992)	
	BC	Biesinger et al., Stable Growth Transformation of Human T Lymphocytes by Herpesvirus Saimiri, Proc. Natl. Acad. Sci. U.S.A. 89:3116-3119 (1992)	
	BD	Yao et al., Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor, Immunity 3:811-821 (December 1995)	
	BE	Chabaud et al., Enhancing Effect of IL-17 on IL-1 Induced IL-6 and Leukemia Inhibitory Factor Production by Rheumatoid Arthritis Synoviocytes and Its Regulation by Th2 Cytokines1, J. Immunol 161:409-414 (1998)	
✓	BF	Shalom-Barak et al., Interleukin-17-induced Gene Expression in Articular Chondrocytes Is Associated with Activation of Mitogen-activated Protein Kinases and NF-κB*, J. Biol. Chem 273:27467-27473 (October 1998)	

Examiner Signature		Date Considered	3/29/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label:

PTO/SB/08b (08-03)


Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	09/980545		
		Filing Date	03/27/2000		
		First Named Inventor	FRIDMAN, Herve W.		
		Art Unit	1646		
		Examiner Name	Xiaozhen Xie		
Sheet	5	of	5	Attorney Docket Number	SF0941K1 US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
XZ	BG	Jovanovic et al., IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-B and TNF-(alpha), by Human Macrophages, J. Immunol. 160:3513-3521 (1998)	
XZ	BH	Tartour et al., Analysis of Interleukin 6 Gene Expression in Cervical Neoplasia Using a Quantitative Polymerase Chain Reaction Assay: Evidence for Enhanced Interleukin 6 gene Expression in Invasive Carcinoma, Cancer Research 54:6243-6248 (December 1994)	
	BI		
	BJ		
	BK		
	BL		
	BM		
	BN		
	BO		
	BP		

Examiner Signature		Date Considered	3/29/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.